Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus FOLFOXIRI vs FOLFOXIRI in first-line RAS wild-type metastatic colorectal cancer
2009-017731-17Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Combined objective response rate for patient cohort I and II. Started Oct 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-017731-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017731-17.